Related Experiment Video
Updated: Aug 28, 2025

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells
Published on: July 30, 2020
Identification and Screening of Novel Anti-Cancer Compounds for Aurora Kinase-A from Chemical Database
Ipsa A Singh1, Kiran Bharat Lokhande1, K Venkateswara Swamy2
1Bioinformatics Research Laboratory, Dr. D. Y. Patil Biotechnology and Bioinformatics Institute, Dr. D. Y. Patil Vidyapeeth, Pune, India.
Abstract:
Aurora kinase is a group of enzymes that belongs to a serine-threonine family and plays a critical role in cellular division. Aurora Kinase A is overexpressed and distributed beyond the nucleus and is involved in tumorigenesis. Flavones are a class of flavonoids that are present in plants that show anticancer activity. Similar compounds of 2'Fluoroflavones are retrieved from the PubChem database. Then drug-like filters viz. REOS and PAINS were applied to remove toxic compounds using Canvas software, resulting in 3882 compounds being subjected to Glide docking with Aurora kinase A. The lead compounds were selected on the merit of hydrogen bonding, salt bridge, as well as pi-pi interactions, 4-(6-Fluoro-4-oxychromen-2yl) benzoic acid, has been found one of the best molecules from docking studies. The binding mode of the lead compound with AURKA reveals that the amino acid residues viz, Lys162, Ala213, and His280 are more important for binding with the binding affinity of -11.760 kcal/mol. The molecular dynamics simulations of 100 ns were done, which shows the mean RMSD value of 1.77 Å for all 3 complexes of the protein and Fluoroflavone and its analogs. This shows that Fluoroflavone and its 2 best analogs are tightly attached to the active sites and thus have conformational stability. Our finding suggests that 4-(6-fluoro-4-oxochromen-2-yl)benzoic acid and 4-(4-Oxochromen-2-yl)benzoate can be further used in vitro and in vivo experiments and can probably serve as a novel drug for cancer treatment.
Insights
Novel fluoroflavones show promise as anticancer drugs by inhibiting Aurora Kinase A, a key enzyme in cell division and tumor growth. Molecular docking and simulations confirm strong binding affinity, suggesting potential for new cancer therapies.
Area of Science:
- Biochemistry
- Medicinal Chemistry
- Molecular Biology
Background:
- Aurora kinase is a serine-threonine enzyme crucial for cell division.
- Aurora Kinase A overexpression is linked to tumorigenesis.
- Flavones, plant-derived flavonoids, exhibit anticancer properties.
Purpose of the Study:
- To identify novel fluoroflavone derivatives with potential anticancer activity against Aurora Kinase A.
- To investigate the binding interactions and stability of lead compounds with Aurora Kinase A.
Main Methods:
- Virtual screening of 2'Fluoroflavones from PubChem.
- Application of drug-like filters (REOS, PAINS) and Glide docking with Aurora Kinase A.
- Molecular dynamics simulations (100 ns) to assess complex stability.
Main Results:
- Identified 4-(6-Fluoro-4-oxychromen-2yl) benzoic acid as a lead compound with a binding affinity of -11.760 kcal/mol.
- Key interactions involve amino acid residues Lys162, Ala213, and His280.
- Molecular dynamics simulations demonstrated conformational stability and tight binding of fluoroflavones to the active site.
Conclusions:
- 4-(6-fluoro-4-oxochromen-2-yl)benzoic acid and its analogs show significant potential as anticancer agents.
- These compounds warrant further investigation in in vitro and in vivo experiments for cancer treatment development.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Inhibition of Cdk Activity

